BTSG Earnings Beats Mask Margin Stagnation at 27.6x
BrightSpring posted its third consecutive earnings beat in Q3 2026, with EPS coming in 14.9% ahead of consensus while revenue grew 26.4% year-over-year. Yet gross margins remain flat at 12.5%, and the
BTSG's 11.3% Rally Pits Earnings Beat Against Thin Margin
NEW YORK, November 8 —
BrightSpring Health Services, Inc. (BTSG) posted a 14.9% Q3 2026 EPS beat, yet the stock reached 27.6x forward earnings on 12.5% gross margins, a multiple pricing in a margin transformation the income statement has not begun. Shares jumped 11.3% that week; no insider has bought on the open market.
- Q3 2026 EPS $0.54 vs. consensus (+14.9%); third consecutive beat, per 8-K.
- TTM revenue $15.25B, +26.4% YoY; gross margin 12.5%; 12 cents retained per revenue dollar.
- Zero insider open-market purchases in 90 days; CEO disposed 36,355 shares five days before earnings.
Three Beats, No Margin Expansion
BrightSpring, which delivers infused medications and specialty pharmacy under the Pharmerica brand alongside home health and behavioral therapy through its Provider Services arm, grew TTM revenue to $15.25 billion at a 26.4% annual clip. The three-quarter beat streak, surprises of 25.9%, 12.6%, and 14.9%, signals real momentum. What it has not produced is margin expansion. Gross margin sits at 12.5%, a direct result of the structural economics of care delivered by 23,500 employees: each incremental revenue dollar absorbs the same labor-intensive cost base. At 27.6x forward earnings, the market has priced a business that does not yet appear in the income statement.
The Insider Signal No Rally Erases
BrightSpring's insiders have been consistent sellers. Pharmerica president Scott Greenwell sold 15,099 shares at $57.91 on September 14 for $874,383, exercising options at $22.27 the same day to capture the spread. CEO Jon Rousseau disposed of 36,355 shares at $60.11 on October 25, five days before the Q3 earnings release, in a tax-withholding transaction worth million. Both prices sit below the current $67.15, meaning each executive has since left appreciation on the table. The pattern that matters, though, is the absence: across 90 days, with the stock rising, not one insider bought a single share on the open market.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| BTSG | $13.4B | 27.6x | +100.0% |
| SNEX | $6.6B | 11.5x | +34.7% |
| PACS | $7.9B | 17.7x | +296.8% |
| WAY | $5.5B | 15.0x | -21.5% |
| PARR | $3.4B | 4.1x | +57.1% |
| INDV | $4.3B | 8.0x | -15.3% |
Short Interest Has a Point
BrightSpring carries $1.66 billion in net debt against TTM free cash flow of billion, manageable, but with no cushion if revenue growth slows. The equity case requires gross margin to widen; at a near-30x forward multiple, EPS beats alone do not close a gap of that magnitude. The specific test arrives with Q4 results: if margin fails to expand while EPS beats continue, the multiple compresses regardless of the headline number. Short interest at 8.9% of float is positioned for exactly that outcome; the consensus target of $83.21 (24% upside) is not. Run the free BrightSpring Health Services, Inc. deep-dive →, or model the case in the DCF calculator.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What were BTSG earnings in Q3 2026?
BrightSpring reported Q3 2026 EPS of $0.54 versus consensus of $0.4709, marking a 14.9% beat. This was the company's third consecutive earnings beat, with prior surprises of 25.9% and 12.6%.
Why did BTSG stock rise 11.3%?
BrightSpring's stock jumped 11.3% following the earnings beat announcement. However, the rally does not reflect fundamental improvements in the business, as gross margins remained flat at 12.5%.
What is concerning about BTSG's valuation?
At 27.6x forward earnings, BrightSpring's multiple prices in margin expansion that has not yet appeared on the income statement. Gross margin stands at just 12.5%, and insiders have not purchased shares in 90 days despite the rally.
Are insiders buying BTSG stock?
No. CEO Jon Rousseau sold 36,355 shares at $60.11 on October 25, five days before earnings, and Pharmerica president Scott Greenwell sold 15,099 shares at $57.91 on September 14. Across 90 days with the stock rising, not one insider has purchased shares on the open market.
What debt does BrightSpring carry?
BrightSpring carries $1.66 billion in net debt against trailing-twelve-month free cash flow of $1.109 billion. This leaves limited cushion if revenue growth decelerates.
BrightSpring Health Services filed a Q3 2026 earnings 8-K on October 30 showing EPS of $0.54 against a $0.4709 consensus estimate — a 14.9% beat that extended a three-quarter earnings streak. Shares jumped 11.3% in a week, but the stock now prices at 27.6x forward earnings on gross margins of just 12.5%, and no insider has purchased a single share on the open market in 90 days.